1 hour ago
3
Vandita Jadeja
Mon, May 4, 2026 astatine 7:55 AM CDT 5 min read
Quick Read
-
AbbVie (ABBV) reported $15B successful Q1 revenue, up 12.4% twelvemonth implicit year, with immunology drugs Skyrizi ($4.5B) and Rinvoq ($2.1B) driving growth, and raised full-year adjusted EPS guidance to $14.08-$14.28.
-
Coca-Cola (KO) delivered 12% Q1 gross maturation to $12.47B with 10% integrated income maturation and 18% adjusted EPS increase, portion PepsiCo (PEP) posted 8.5% Q1 gross maturation and 24% operating nett leap with 54 consecutive years of dividend increases.
-
Strong Q1 net crossed each 3 dividend stocks, combined with accordant dividend maturation and charismatic yields (AbbVie 3.27%, Coca-Cola 2.69%, PepsiCo 3.61%), marque them compelling options for income investors seeking stableness during marketplace volatility.
-
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.
Dividend stocks tin beryllium a pillar for semipermanent investing, generating passive income and offering stableness adjacent during pugnacious environments. The existent marketplace volatility and geopolitical unrest person attracted investors to dividend stocks. However, each dividend banal isn’t the same.
You mightiness find respective high-yield companies, but it makes consciousness to prime stocks that person consistently paid dividends and raised their payouts. This shows that the institution is committed to rewarding shareholders. A generous output attracts investors, and there’s a accidental for appreciation successful starring stocks. I’ve been a dividend capitalist for decades, and present are the stocks I support buying.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.
AbbVie
Pharmaceutical elephantine AbbVie (NYSE:ABBV | ABBV Price Prediction) is known for a lineup of drugs that dainty autoimmune diseases, migraines, cancer, and more. It has an awesome pipeline, and 12 of the company’s drugs person generated $1 cardinal successful income successful the past year. While it is dealing with patent expirations, it besides has the accidental for different cause approvals. The institution tin grip the changing marketplace situations and has products that tin make dependable gross growth.
AbbVie precocious reported results and bushed expectations. It reported a gross of $15 billion, up 12.4% twelvemonth implicit year. The adjusted EPS came successful astatine $2.65, immunology being the apical driver, generating $7.3 cardinal successful revenue. Skyrizi brought successful $4.5 billion, and Rinvoq generated $2.1 billion.
AbbVie reported beardown request crossed antithetic segments and managed to equilibrium the dip successful Humira sales. It raised the full-year gross guidance to $67.3 cardinal and accrued the adjusted EPS guidance to $14.08-$14.28, up by $300 cardinal from the erstwhile guidance.
English (CA) · 
English (US) · 
Spanish (MX) ·